Dihydrofoliamenthin



Compound IDCDAMM01633
Common nameDihydrofoliamenthin
IUPAC name[5-ethenyl-1-oxo-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-3-yl] 8-hydroxy-2,6-dimethyloct-6-enoate
Molecular formulaC26H38O12

Experimental data

Retention time2.58
Adduct[M+H]+
Actual mz543.24
Theoretical mz543.243
Error5.29
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.0668

Identifiers and class information

Inchi keyMLZWMRAJMJNMHR-LCKCCRTJNA-N
SmilesO=C1OC(OC(=O)C(C)CCCC(=CCO)C)CC2C1=COC(OC3OC(CO)C(O)C(O)C3O)C2C=C
SuperclassLipids and lipid-like molecules
ClassFatty Acyls

Pharmacokinetic properties

Number of descriptor values(#stars)4
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)16
Number of reactive functional groups (#rtvFG)5
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)542.579
Computed dipole moment(dipole)2.816
Total solvent accessible surface area (SASA)884.986
Hydrophobic component of SASA (FOSA)516.321
Hydrophilic component of SASA (FISA)299.69
Pie component of the SASA (PISA)68.976
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1644.14
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)18.6
Free energy of solvation of dipole (dip^2/V)0.0048231
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0469961
Globularity descriptor (glob)0.761238
Predicted polarizability in cubic angstroms (QPpolrz)50.029
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.486
Predicted octanol/gas partition coefficient (QPlogPoct)34.099
Predicted water/gas partition coefficient (QPlogPw)26.471
Predicted octanol/water partition coefficient (QPlogPo/w)-0.445
Predicted aqueous solubility (QPlogS)-3.334
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.13
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.724
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)14.254
Predicted brain/blood partition coefficient (QPlogBB)-3.849
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)5
Predicted skin permeability, log Kp (QPlogKp)-5.264
PM3 calculated ionization potential (IP(ev))9.913
PM3 calculated electron affinity (EA(eV))0.361
Number of likely metabolic reactions (#metab)10
Prediction of binding to human serum albumin (QPlogKhsa)-1.149
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)19.077
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)200.087
Number of nitrogen and oxygen atoms (#NandO)12
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P29274ADORA2AAdenosine A2a receptorT77365SwissTargetPrediction
P30542ADORA1Adenosine A1 receptorT92072SwissTargetPrediction
P0DMS8ADORA3Adenosine A3 receptorT36059SwissTargetPrediction
P13866SLC5A1Sodium/glucose cotransporter 1T54771SwissTargetPrediction
Q9BZP6CHIAAcidic mammalian chitinase (by homology)T51597SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
O43868SLC28A2Sodium/nucleoside cotransporter 2T94627SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T77365DI0319Orthostatic hypotension[ICD-11: BA21]P29274ADORA2A
T77365DI0331Parkinsonism[ICD-11: 8A00]P29274ADORA2A
T77365DI0359Radionuclide imaging[ICD-11: N.A.]P29274ADORA2A
T92072DI0319Orthostatic hypotension[ICD-11: BA21]P30542ADORA1
T36059DI0351Psoriasis[ICD-11: EA90]P0DMS8ADORA3
T36059DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P0DMS8ADORA3
T54771DI0120Diabetes mellitus[ICD-11: 5A10]P13866SLC5A1
T54771DI0175Heart failure[ICD-11: BD10-BD1Z]P13866SLC5A1
T54771DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P13866SLC5A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR

Copyright © 2025